Missouri Judge Approves $7.25 Billion Bayer Roundup Settlement
A Missouri judge approved a nationwide settlement Friday that would provide up to $7.25 billion for people alleging Roundup weed killer caused their cancer, German-based agrochemical maker Bayer said Friday.
The agreement covers eligible people already diagnosed with non-Hodgkin lymphoma and others diagnosed during a specified future period. Bayer says regulators have found glyphosate is not carcinogenic and that the settlement contains no admission of liability or wrongdoing, according to the release.
Individual compensation would depend on factors including exposure, age at diagnosis, and illness severity. Average payments could range from $10,000 to $165,000.
The approval follows a June Supreme Court ruling that narrowed the legal options available to people pursuing Roundup claims. The justices ruled 7–2 that federal pesticide law preempts state failure-to-warn claims that would require a cancer warning on Roundup’s EPA-approved label.
Bayer said its Monsanto subsidiary will fund the program through annual payments that decline over time and are subject to caps. The approval remains subject to appeal, which would suspend further Monsanto payments until challenges are resolved.
“The Court's final approval is a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation,” Bayer CEO Bill Anderson said in the release.
Eligibility requires alleged Roundup exposure before Feb. 17, 2026, and either an existing non-Hodgkin lymphoma diagnosis or one received within 16 years after the agreement takes effect.
Among those potentially receiving higher compensation are agricultural, industrial and turf workers with prolonged exposure who developed aggressive disease before age 60. Their payments could average $165,000, compared with an average of $10,000 for people diagnosed at 78 or older.
St. Louis Circuit Judge Timothy Boyer described average individual payments as “fair and adequate” and warned that rejecting the agreement carried a risk of Bayer seeking bankruptcy protection. The settlement includes $600 million in attorneys’ fees.
“Today’s final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice,” Christopher A. Seeger, a court-appointed attorney representing cancer patients, said.
Critics argued the agreement limits future claimants too severely. Attorney Gerson Smoger objected at a September hearing that it binds people for decades without access to punitive damages while leaving the product available.
Bayer inherited Roundup and its growing legal exposure when it purchased Monsanto in 2018. About 200,000 related claims have been made against Bayer, and the company previously set aside $16 billion for Roundup legal costs.
The dispute centers on glyphosate, the active ingredient in Monsanto’s original Roundup, introduced in 1974. The World Health Organization’s cancer research agency classified glyphosate as “probably carcinogenic” in 2015, while the Environmental Protection Agency determined it is unlikely to cause cancer when used as directed.
Bayer has removed glyphosate from newer residential Roundup formulations.
The agreement does not end every courtroom fight. Bayer expects relatively few eligible claimants to opt out and says Monsanto will continue defending remaining cases.
A Missouri jury sided with Bayer’s Monsanto unit in late October on design defect, negligence, and fraud claims in the first Roundup trial following the Supreme Court’s decision in Monsanto v. Durnell.
Sources
- washingtonexaminer.com: Settlement for $7 billion approved over Roundup cancer claims
- justthenews.com: Judge approves $7 billion nationwide settlement regarding Roundup cancer claims | Just The News
- ntd.com: Judge Approves $7.25 Billion Bayer Settlement Over Claims Roundup Caused Cancer | NTD
This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.


